MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SUPN stock logo

SUPN

Supernus Pharmaceuticals, Inc.

$54.73
-1.02
 (-1.83%)
Exchange:  
Market Cap:   3.138B
Shares Outstanding:   13.855M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Jack A. Khattar
Full Time Employees:  674
Address: 
9715 Key West Avenue
Rockville
MD
20850
US
Website:  https://www.supernus.com
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson’s disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

🔒 You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Current Key Metrics

🔒 You are currently logged out

Login

It’s free

Forward P/E Ratios

🔒 You are currently logged out

Login

It’s free

SWOT Analysis

🔒 You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator


Calculate SUPN Intrinsic Value

🔒 You are currently logged out

Login

It’s free

See in Nexus

Relevant news

25-02-2026 04:27
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
12-02-2026 16:35
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
08-12-2025 15:57
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
21-11-2025 16:06
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
04-11-2025 21:31
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
29-10-2025 13:01
Here’s Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read